Reducing early portfolio risk with retrosynthesis White Paper

Rising costs, low success rates, and increasing competition are intensifying pressure on early drug development decisions. Yet synthetic feasibility is often overlooked as a source of early portfolio risk, leading to costly delays or failures later.

This white paper highlights feasibility as a key source of portfolio risk and shows how early retrosynthetic analysis can improve candidate selection by revealing route complexity, precedent, and supply constraints.

Read the white paper to understand:

• Why synthetic feasibility is a hidden but costly source of early portfolio risk
• How retrosynthetic analysis reveals route complexity, precedent, and supply constraints across candidates
• Where AI-enabled retrosynthesis adds the most value across the discovery workflow
• What capabilities to look for when selecting a retrosynthesis tool

Download the white paper now and discover how to maintain your competitive advantage.